Table 4.
With presarcopenia and JIS score >3 (n = 17) | With presarcopenia and JIS score <2 (n = 26) | Without presarcopenia and JIS score >3 (n = 31) | Without presarcopenia and JIS score <2 (n = 79) | |
---|---|---|---|---|
Age: years, mean ± SD | 68 ± 8.0 | 75 ± 8.6 | 71 ± 10 | 75 ± 8.6 |
Male: n (%) | 15 (88) | 25 (96) | 25 (81) | 49 (62) |
BMI, mean ± SD | 20 ± 3.2 | 22 ± 3.2 | 22 ± 3.6 | 23 ± 3.1 |
Complicated with diabetes: n (%) | 6 (35) | 6 (23) | 8 (26) | 24 (30) |
Maximum size of HCC nodule in the liver: mm, median (range in IQR) | 105(50–120) | 29(20–52) | 67(40–95) | 25(15–41) |
Number of HCC nodules: 1/2/3/4 or more, n | 7/3/0/7 | 15/6/4/0 | 7/8/2/14 | 55/8/8/8 |
Presence of ascites: n (%) | 9(53) | 5(19) | 12(39) | 4(5) |
Presence of hepatic encephalopathy: n (%) | 1(6) | 0(0) | 4(13) | 3(4) |
Child-Pugh grade: A/B/C: n | 2/10/5 | 22/2/2 | 10/15/6 | 59/19/1 |
HCC stage: 1/2/3/4: n | 0/2/4/11 | 4/14/8/0 | 0/1/8/22 | 22/45/12/0 |
JIS score: 0/1/2/3/4/5: n | 0/0/0/7/8/2 | 3/11/12/0/0/0 | 0/0/0/18/9/4 | 12/45/22/0/0/0 |
Albumin: g/dl, mean ± SD | 2.9 ± 0.61 | 3.8 ± 0.64 | 3.3 ± 0.54 | 3.7 ± 0.52 |
Total bilirubin: g/dl, mean ± SD | 2.8 ± 0.68 | 0.89 ± 0.37 | 2.4 ± 2.9 | 1.0 ± 0.57 |
γ-GTP: U/l, mean ± SD | 285 ± 318 | 69 ± 70 | 257 ± 265 | 94 ± 108 |
Prothrombin time: %, mean ± SD | 72 ± 22 | 86 ± 19 | 76 ± 19 | 86 ± 18 |
AFP: ng/ml, median (range in IQR) | 284(17–28457) | 39(6.1–127) | 803(37–7781) | 13(4.8–57) |
AFP L3 index: %, median (range in IQR) | 54(25–74) | 6.8(0.5–28) | 30(6.2–62) | 4.6(0.5–12) |
PIVKA-α: mAU/ml, median (range in IQR) | 9618(6251–24752) | 99(24–1702) | 2018(125–17501) | 45(20–314) |
Taking BCAA: n (%) | 6(35) | 4(15) | 11(36) | 22(28) |
Values are mean ± standard deviation. NASH; nonalcoholic steatohepatitis, BMI; body mass index, HCC; hepatocellular carcinoma, ALT; alanine aminotransferase, AFP; alpha-fetoprotein, AFP L3 fraction; Lens culinaris agglutinin-reactive fraction of AFP, PIVKA-II; prothrombin induced by vitamin K absence II.